Blog

New Division to Combine Specialized Commercial Expertise with Epique’s Disruptive, Tech-Forward Brokerage Model

HOUSTON, TX / ACCESS Newswire / July 14, 2025 / Epique Realty today announced its strategic expansion into the commercial real estate sector with the launch of Epique CORE Commercial. Unveiled at the 2025 Epique PowerCON, CORE is an elite division designed to bring Epique’s disruptive, agent-centric model to commercial real estate practitioners, providing them with extraordinary support and award-winning AI technology.

CORE is built to serve the unique needs of commercial agents, offering a new standard of excellence in a sector ripe for innovation.

“The commercial real estate world has been underserved by innovation for too long,” said Christopher Miller, COO and Co-Founder of Epique Realty. “It’s a space often dominated by legacy models that don’t fully prioritize the agent’s individual success. With CORE, we are changing that. We are combining proven commercial expertise with the speed, technology, and radical support of the Epique platform to create an environment where entrepreneurial commercial agents can thrive like never before.”

Membership in CORE is selective, ensuring a network of highly skilled professionals. These specialists will receive exclusive, tailored support, including:

• Dedicated Coaching and Mentorship from veteran commercial real estate leaders.

• Specialized Training focused on mastering the complexities of the CRE market, from legal and liability insights to advanced deal structuring.

• Exclusive Tools & Resources designed specifically for commercial transactions and analytics.

While CORE provides specialized support, its members are also supercharged by Epique’s powerful, award-winning platform. This includes full access to the company’s comprehensive suite of free benefits, such as advanced AI tools, free transaction coordination, professional listing photography, revenue share, and stock ownership opportunities.

Epique CORE is more than a new division; it is a premier entity designed for top-tier talent. Entry is by invitation and waitlist only to maintain a community dedicated to excellence and deep market expertise.

For more information: https://epiquecore.io/ or email CORE@epiquerealty.com

About Epique Realty

Epique Realty is one of the fastest-growing real estate brokers in history, now operating in all fifty states with over 4,000 agents, and global expansion is underway. Its revolutionary agent-first model provides free extensive benefits with award-winning AI and a culture of radical generosity. By questioning industry norms and putting agents at the center of its universe, Epique is not just transforming the real estate market-it is defining the future. #BeEpique

Media Contact
Barbara Simpson | PR and Communications
281-773-7842 | Barbara@EpiqueRealty.com

https://www.instagram.com/epiquerealty/
https://www.facebook.com/epiquerealty
https://www.linkedin.com/company/epique-realty/mycompany/
https://www.youtube.com/@epiquerealty

SOURCE: Epique Realty

View the original press release on ACCESS Newswire

A revolutionary, in-house utility and home service concierge

HOUSTON, TX / ACCESS Newswire / July 14, 2025 / Epique Realty recently announced the upcoming launch of Epique Connect, a revolutionary, in-house utility and home service concierge designed to eliminate the stress of moving for clients and save agents valuable time. Unveiled at the 2025 PowerCON, the new service addresses a critical pain point in the homebuying process, where research shows 75% of clients find setting up utilities to be a stressful and confusing experience.

Epique Connect provides a complimentary, white-glove service that manages the setup of all essential home services – including electricity, gas, water, internet, and TV, in one streamlined, personalized phone call.

“Our philosophy is simple: identify the biggest points of friction in the real estate process and build a solution,” said Janice Delcid, CFO and Co-Founder of Epique Realty. “The agent’s job doesn’t end at the closing table, and a client’s positive experience shouldn’t either. Epique Connect ensures the final mile of the homeownership journey is seamless and positive, which reflects brilliantly on our agents and saves them hours of logistical work. It’s the ultimate expression of our commitment to supporting the entire client relationship.”

The Epique Connect experience is designed around trust and convenience:

• An agent submits their client’s information through a simple, branded portal.

• A dedicated, Epique-trained concierge contacts the client to coordinate all their needs.

• Unlike many third-party services, the experience is built on a “no spam, no upselling” promise, just genuine, helpful support.

This service creates a powerful win-win. Clients receive a stress-free moving experience that leaves a lasting positive impression, while agents get back up to three hours per transaction and are equipped with a premium service that helps drive repeat and referral business.

Set to begin its rollout in Fall 2025, Epique Connect is built as an evolving platform, with future plans to integrate solar concierge, smart home setup, and moving services. It’s one more way Epique is going beyond the transaction to provide support that moves with the client and convenience that sets the agent apart.

For more information: www.EpiqueRealty.com

About Epique Realty

Epique Realty is one of the fastest-growing real estate brokers in history, now operating in all fifty states with over 4,000 agents, and global expansion is underway. Its revolutionary agent-first model provides free extensive benefits with award-winning AI and a culture of radical generosity. By questioning industry norms and putting agents at the center of its universe, Epique is not just transforming the real estate market – it is defining the future. #BeEpique

Media Contact
Barbara Simpson | PR and Communications
281-773-7842 | Barbara@EpiqueRealty.com

https://www.instagram.com/epiquerealty/
https://www.facebook.com/epiquerealty
https://www.linkedin.com/company/epique-realty/mycompany/
https://www.youtube.com/@epiquerealty

SOURCE: Epique Realty

View the original press release on ACCESS Newswire

Clear Start Tax breaks down the hidden tax risks of sudden income changes – and how to recover before penalties build up.

IRVINE, CA / ACCESS Newswire / July 14, 2025 / In a time of ongoing layoffs, side gigs, and economic uncertainty, many Americans are finding themselves hit with unexpected tax bills, often months after their financial crisis. According to Clear Start Tax, job loss doesn’t just strain household income – it can create IRS debt from unreported unemployment income, early 401(k) withdrawals, and untracked freelance or gig earnings.

“People are shocked when they owe the IRS after a year of financial hardship,” said the Head of Client Solutions at Clear Start Tax. “But job loss often leads to survival-based choices that trigger tax issues down the line. We help people correct those filings and get back on track.”

How Job Loss Can Lead to IRS Debt

Many Americans assume that because they weren’t working full-time, they won’t owe much – or anything – in taxes. But the reality is that many forms of income during unemployment are taxable, and without proper withholding or planning, a bill can build up quickly.

Clear Start Tax identifies the most common sources of unexpected IRS debt after job loss:

• Unemployment Benefits – These are fully taxable at the federal level, yet often under-withheld.

• 401(k) or IRA Withdrawals – Early withdrawals (before age 59½) typically carry a 10% penalty plus regular income tax.

• Freelance, Gig, or Contract Work – Without employer withholding, taxpayers are responsible for their own income and self-employment taxes.

• Missed Quarterly Payments – Independent workers or those with side gigs must estimate and pay taxes every quarter, or face penalties.

“In tough times, people do what they must to stay afloat – whether that’s taking from retirement or picking up gig work,” said the Head of Client Solutions at Clear Start Tax. “But without the right tax planning, those decisions can come back as unexpected IRS debt.”

IRS Notices Are Increasing – Take Action Before It’s Too Late

When taxes go unpaid or underreported, the IRS often responds with letters like CP14 (balance due), CP2000 (underreported income), or Intent to Levy notices. These letters can look intimidating, but they’re also an opportunity to fix the issue before it escalates.

According to the IRS, more than 10 million taxpayers received CP14 notices in 2024 alone, many tied to misreported unemployment and self-employment income.

Tax experts at Clear Start Tax recommend:

• Reviewing all income sources – including unemployment, withdrawals, and side gigs

• Gathering records from payment apps, gig platforms, and retirement account statements

• Amending prior-year returns if income was missed or misclassified

• Responding promptly to IRS notices, especially if you can’t pay the full amount

• Exploring relief options to reduce penalties or negotiate a settlement

The IRS Fresh Start Program Can Offer a Path Forward

Taxpayers who are struggling financially may qualify for IRS Fresh Start relief, which can help reduce or settle their tax debt. Clear Start Tax works with clients to evaluate eligibility and build a customized case based on income, expenses, and current hardship.

The program is designed to help taxpayers in hardship situations. Depending on eligibility, it may provide:

• Payment plans based on current ability to pay

• Reduction or removal of penalties and interest

• Settlement for less than the full amount owed through an Offer in Compromise

By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.

Don’t Let a Difficult Year Turn Into Long-Term IRS Trouble

Clear Start Tax emphasizes that it’s never too late to take action. Whether the debt came from job loss, side income, or early retirement withdrawals, there are programs available to help people rebuild financially and avoid further IRS consequences.

“We’ve helped people who thought they were ruined financially after losing a job or draining a retirement account,” said the Head of Client Solutions. “With the right plan, it’s possible to reduce what you owe and rebuild financially.”

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/
(888) 710-3533

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

DALLAS–FORT WORTH, TX / ACCESS Newswire / July 14, 2025 / ABC Plumbing, a trusted family-owned company with over three decades of expertise, has won the 2025 Consumer Choice Award in the Drainage and Sewer Services category for the Dallas-Fort Worth area. This recognition underscores ABC Plumbing’s long-standing commitment to delivering reliable, high-quality plumbing solutions with integrity, craftsmanship, and 5-star customer care.

Proudly serving Tarrant County and surrounding communities since the early 1990s, ABC Plumbing has become a go-to partner for homeowners, businesses, and remodelers who want peace of mind and skilled workmanship at fair prices.

A Tradition of Quality and Trust
Since founding ABC Plumbing, owner and operator Richard Lewis has built the company on a clear promise: provide top-quality plumbing with a personal touch, at a price customers can feel good about. From drain blockages and sewer line repairs to full system upgrades and remodels, the company handles each job with genuine care and the highest standards.

“Winning the Consumer Choice Award means everything to us because it shows that our neighbors appreciate our commitment to honest work, fair pricing, and exceptional service,” said Richard Lewis, Owner and Operator of ABC Plumbing. “At ABC Plumbing, you’ll always get 5-Star Service at 2-Star Pricing – that’s been our promise since day one.”

Comprehensive Drainage and Sewer Solutions

ABC Plumbing offers a wide range of drainage and sewer services designed to keep homes and businesses safe, sanitary, and running smoothly. Homeowners count on ABC for expert drain cleaning, thorough inspections, sewer repairs, and cost-effective replacements that prevent bigger problems down the line.

For commercial properties and new construction, ABC’s skilled crews collaborate with contractors and property managers to deliver dependable solutions tailored to each site’s unique needs.

Emergency Help When It Matters Most
Plumbing issues don’t follow a 9-to-5 schedule – which is why ABC Plumbing provides reliable emergency services whenever customers need them most. Whether it’s an unexpected sewer backup, a burst pipe after hours, or a drain problem on a holiday, the team responds quickly to restore safety and peace of mind.

Expertise in Residential, Commercial, and Remodeling Projects
In addition to drainage and sewer work, ABC Plumbing’s licensed technicians handle general plumbing for everything from everyday leaks and faucet upgrades to complete plumbing system designs for remodels and new builds. The company’s investment in ongoing training means customers always benefit from up-to-date skills and solutions that meet current codes and best practices.

Fair, Transparent Service
Richard Lewis’s vision of “5-Star Service at 2-Star Pricing” is at the heart of everything ABC Plumbing does. Customers appreciate clear estimates, honest recommendations, and no unexpected add-ons – just straightforward solutions at prices that make sense.

This dedication to doing the right thing has earned ABC Plumbing a loyal customer base and countless referrals across the Dallas-Fort Worth area.

Rooted in the Community
As a locally owned and operated business, ABC Plumbing is proud to serve Tarrant County families and businesses with integrity and personal care. The company supports local causes, hires local talent, and values the trust it has built over three decades of continuous service.

Looking Ahead
With this Consumer Choice Award win, ABC Plumbing plans to expand its team of licensed technicians, add new eco-friendly drainage and sewer solutions, and continue investing in advanced equipment that improves efficiency and reduces costs for customers.

One thing that won’t change? Richard Lewis’s commitment to ensuring every customer receives quality plumbing backed by honesty, respect, and pride in a job well done.

To learn more about ABC Plumbing’s drainage and sewer services, request an estimate, or book emergency help, visit www.abcplumbingtx.com.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

bGen was selected as the thermal energy storage system for a large-scale solar energy project led by a top European utility company

Marks the second bGen project within two months selected to receive European Union non-dilutive project funding

5 MWe bGen expected to contribute to the avoidance of 1.45 M tons of CO₂ equivalent over 10 years and a 104% increase in energy efficiency

Project configuration enables effective replacement of fossil-fuel-based steam generation in industrial processes

ROSH HAAYIN, ISRAEL / ACCESS Newswire / July 14, 2025 / Brenmiller Energy Ltd. (Nasdaq:BNRG), (the “Company”, “Brenmiller” or “Brenmiller Energy”) a leading global provider of Thermal Energy Storage (“TES”) solutions for industrial and utility customers, announced today that a large-scale solar energy project which integrates the Company’s bGen™ TES solution has been selected to receive funding from the European Union’s Innovation Fund 2023 Call for Net Zero Technologies. The project is now advancing toward the grant agreement phase, subject to the conclusion of off-take agreements between the project lead and end customers.

The project, which is led by and involves some of the world’s largest energy companies, aims to accelerate the deployment of sustainable heat solutions in Europe. As part of the project, Brenmiller Europe S.L. (“Brenmiller Europe”), the Company’s Spain-based joint venture, is expected to supply distributed bGen™️ TES systems with a total electrical charge capacity of approximately 5 MWe, representing approximately €4 million in revenues to Brenmiller Europe for the equipment sale.

“We are proud that bGen™ is the TES system of choice for one the world’s top energy companies leading this project. Funding from the European Union’s Innovation Fund accelerates this pioneering initiative, which we believe is an important step in an ambitious plan that may lead to replication of the concept across Europe’s industrial sector,” said Avi Brenmiller, Chairman and Chief Executive Officer at Brenmiller Energy.

“This project serves as a great example of the kind of high-profile, large-scale projects in our commercial pipeline that are advancing into project funding and potentially converting into revenues. We view this development as a significant milestone in expanding our presence in the European energy market, particularly in the fields of industrial heat and steam decarbonization,” Mr. Brenmiller concluded.

Based on documents filed with the European Union Climate, Infrastructure, and Environment Executive Agency, the project is expected to generate a 104% increase in energy efficiency supplying sustainable heat to industry by decoupling steam demand from power consumption. The project is also expected to avoid more than 1.45 million tons of CO₂ equivalent over its first ten years of operation. This innovative, integrated solution combines renewable energy, TES, and high-temperature heat pumps, significantly boosting the use of green heat to power industry.

About bGen™

bGen™ ZERO is Brenmiller’s TES system, which converts electricity into heat to power sustainable industrial processes at a price that is competitive with natural gas. The bGen™ ZERO charges by capturing low-cost electricity from renewables or the grid and stores it in crushed rocks. It then discharges steam, hot water, or hot air on demand according to customer requirements. The bGen™ ZERO also supports the development of utility-scale renewables by providing critical flexibility and grid-balancing capabilities. bGen™ ZERO was named among TIME’s Best Inventions of 2023 in the Green Energy category and won Gold in the Energy Storage and Management category at the 2025 Edison Awards.

About Brenmiller Energy Ltd.

Brenmiller Energy helps energy-intensive industries and power producers end their reliance on fossil fuel boilers. Brenmiller’s patented bGen™ ZERO thermal battery is a modular and scalable energy storage system that turns renewable electricity into zero-emission heat. It charges using low-cost renewable electricity and discharges a continuous supply of heat on demand and according to its customers’ needs. The most experienced thermal battery developer on the market, Brenmiller operates the world’s only gigafactory for thermal battery production and is trusted by leading multinational energy companies. For more information visit the Company’s website at https://bren-energy.com/ and follow the company on X and LinkedIn.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements when discussing: that the Company’s bGen™ systems will receive funding by the European Union; that the EU grant may potentially lead to revenues; 5 MWe bGen™ is expected to contribute to the avoidance of 1.45 million tons of CO₂ equivalent over 10 years; that the project is expected to result in a 104% increase in energy efficiency; that the project configuration is expected to enable effective replacement of fossil-fuel-based steam generation in industrial processes; that the project is advancing toward the grant agreement phase, subject to off-take agreements between the lead and end customers; that Brenmiller Europe is expected to supply distributed bGen™ TES systems totaling 5 MWe, representing approximately €4 million in revenues; that the project may lead to replication of the concept across Europe’s industrial sector; that the project is expected to supply sustainable heat by decoupling steam demand from power consumption; and that the integrated solution is expected to significantly boost the use of green heat in industry. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect the Company’s results include, but are not limited to: the Company’s planned level of revenues and capital expenditures; risks associated with the adequacy of existing cash resources; the demand for and market acceptance of our products; impact of competitive products and prices; product development, commercialization or technological difficulties; the success or failure of negotiations; trade, legal, social and economic risks; and political, economic and military instability in the Middle East, specifically in Israel. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 4, 2025, which is available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact: investors@bren-energy.com

SOURCE: Brenmiller Energy

View the original press release on ACCESS Newswire

Dateline COO to accelerate development of Colosseum Gold and REE project

SYDNEY, AUSTRALIA AND SAN BERNARDINO COUNTY, CA / ACCESS Newswire / July 14, 2025 / Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF), a North American-focused mining and exploration company, today announced the appointment of Mr. Simon Slesarewich as Chief Operating Officer (COO), effective August 4, 2025.

Mr. Slesarewich brings more than 25 years of international experience in project development, operations, and executive leadership across a range of commodities including gold, base metals, industrial minerals, and bulk commodities. In his new role, he will lead the development of Dateline’s 100%-owned Colosseum Gold and Rare Earth Elements (REE) Project, located in California.

“We are thrilled to have Simon join Dateline as our Chief Operating Officer at this pivotal stage for the Company,” said Stephen Baghdadi, Managing Director of Dateline Resources. “Simon’s decision to come on board, and his significant personal shareholding in Dateline, is a strong vote of confidence in the Colosseum Project and our vision. He brings a wealth of operational experience and a proven track record in taking projects from study through to production. We are confident that his leadership will be instrumental in successfully delivering the Colosseum Gold & REE Project into production and driving significant growth for Dateline.”

Mr. Slesarewich joins Dateline from Thiess, the world’s largest mining services provider with over 12,000 employees globally, where he served in senior executive roles including Operations Director and Project Director. At Thiess, he managed mining contracts generating significant annual revenues and played a key role in the deployment of cutting-edge mining technologies. His career highlights include:

• Large-Scale Operations Management: In his role as Operations Director, he managed two full-service mining contracts with significant annual revenues and more than 1,200 personnel under management.

• Commercial Strategy & Integration: Mr Slesarewich also led the sale of Boardwalk Resources to Whitehaven Coal as part of a $5.2 billion transaction. Other roles have included Head of Integration, where he developed and executed a strategy that achieved cost synergies beyond the acquisition model and unified key business systems across finance, assets, IT, and people. This demonstrates his strong commercial acumen and ability to align large organizations to strategic objectives.

• Mine Development – Middlemount Coal: Earlier in his career, as General Manager, Operations of the Middlemount Coal Mine (Queensland), Mr Slesarewich transformed an undeveloped concept into a fully operational mining operation. He successfully led the greenfield development of Middlemount, a 4.2 Mtpa coking coal mine, overseeing approximately A$500 million in capital construction and a A$400 million annual operating budget, with a workforce of over 800 staff. Under his leadership, Middlemount was developed on time and on budget, and was noted for its significantly lower capital intensity compared to peer projects.

Mr. Slesarewich has personally invested approximately $1 million to purchase Dateline Resources shares, demonstrating a powerful commitment to shareholder interests and strong confidence in the Company’s growth trajectory.

“I am extremely excited to be joining Dateline Resources,” said Mr. Slesarewich. “As an investor in the Company, I firmly believe in the potential of the Colosseum Gold and Rare Earths Project and its strategic importance. I look forward to working closely with Stephen and the team to advance Colosseum through the feasibility study and into construction and production. Together, we will be focused on executing the project effectively and creating significant value for all Dateline shareholders as we move toward production.”

About Dateline Resources Limited

Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF) is an Australian company focused on mining and exploration in North America. The Company owns 100% of the Colosseum Gold-REE Project in California.

The Colosseum Gold Mine is located in the Walker Lane Trend in East San Bernardino County, California. On 6 June 2024, the Company announced to the ASX that the Colosseum Gold mine has a JORC-2012 compliant Mineral Resource estimate of 27.1Mt @ 1.26g/t Au for 1.1Moz. Of the total Mineral Resource, 455koz @ 1.47/t Au (41%) are classified as Measured, 281koz @1.21g/t Au (26%) as Indicated and 364koz @ 1.10g/t Au (33%) as Inferred.

On 23 May 2025, Dateline announced that updated economics for the Colosseum Gold Project generated an NPV_6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz.

The Colosseum is located less than 10km north of the Mountain Rare Earth mine. Planning has commenced on drill testing the REE potential at Colosseum.

Forward-Looking Statements

This announcement may contain “forward-looking statements” concerning Dateline Resources that are subject to risks and uncertainties. Generally, the words “will”, “may”, “should”, “continue”, “believes”, “expects”, “intends”, “anticipates” or similar expressions identify forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond Dateline Resources’ ability to control or estimate precisely, such as future market conditions, changes in regulatory environment and the behavior of other market participants. Dateline Resources cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements. Dateline Resources assumes no obligation and does not undertake any obligation to update or revise publicly any of the forward-looking statements set out herein, whether as a result of new information, future events or otherwise, except to the extent legally required.

Contact Information
Stephen Baghdadi
Managing Director
Dateline Resources Limited
+61 2 9375 2353
info@datelineresources.com.au
www.datelineresources.com.au

Andrew Rowell
White Noise Communications
+61 400 466 226
andrew@whitenoisecomms.com

Follow Dateline on X: @Dateline_DTR

Dateline Resources Limited
Level 29, 2 Chifley Square, Sydney, NSW 2000, Australia

This press release is authorized for release by the Board of Dateline Resources Limited.

SOURCE: Dateline Resources Limited

View the original press release on ACCESS Newswire

DALLAS, TEXAS / ACCESS Newswire / July 14, 2025 / Welborn Garage, a trusted provider of garage and overhead door services across the Dallas-Fort Worth metroplex, has been honored with the 2025 Consumer Choice Award in the Garage & Overhead Doors category for Dallas Central. This distinguished recognition reflects the company’s two-and-a-half decades of dedication to swift repairs, professional installations, and home improvement solutions that elevate both safety and style.

Welborn’s licensed and background-checked technicians are renowned for reliable same-day service on everything from spring and opener repairs to complete door replacements. Since its founding over 25 years ago, the company has expanded beyond basic services to include gate repairs, premium garage floor coatings, and full garage storage upgrades including cabinets, overhead racks, and slat wall systems.

Dependable Expertise Serving the DFW Area

Operating 24/7 throughout Dallas-Fort Worth, Welborn Garage has built a reputation for emergency responsiveness and comprehensive solutions. Whether restoring safety after a broken spring or enhancing a space with commercial-quality flooring and storage, the company consistently delivers workmanship that is both highly skilled and highly rated.

“Our founding principle was simple: do the job right, on the same day you call, and stand behind our work,” said the Welborn Garage team. “Winning the Consumer Choice Award validates those values-and we’re grateful to the homeowners who trust us to care for their most important entryway.”

Quality, Transparency, and Customer Focus

Welborn stands out for its transparent pricing structure, customers receive full estimates before any work begins. The company’s “Welborn Way” guarantees ensure superior craftsmanship, upfront pricing, and lasting peace of mind-no surprises, no hidden fees.

In addition to residential services, their WELCARE maintenance plans and commercial response teams support businesses with roll-up door repairs, loading dock solutions, and ongoing upkeep tailored to operational needs.

Driven by Innovation

Building on this success, Welborn Garage is set to expand its premium offerings with more eco-friendly garage floor coatings, advanced security upgrades, and enhanced smart-home integration for openers and access control, continuing to evolve with homeowner and business needs.

To explore Welborn Garage’s offering, CLICK HERE or visit www.callwelborngarage.com.

About Consumer Choice Award:

Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:

Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

PLANO, TX / ACCESS Newswire / July 14, 2025 / Plano Overhead Garage Door, the most awarded garage door company in the Dallas-Fort Worth area, has once again earned the 2025 Consumer Choice Award in the Garage and Overhead Door category – marking an outstanding 14 consecutive years of recognition for trusted service and superior workmanship. This milestone highlights nearly five decades of dedication to fair pricing, community connection, and exceptional customer care for homeowners throughout North Texas.

Family-owned and operated since 1977, Plano Overhead Garage Door has built its reputation one household at a time, combining professional expertise with a genuine commitment to honesty and convenience. From emergency repairs to complete garage door installations, the company remains the first call for thousands of local families who value quality they can rely on.

Same-Day Service with a Personal Touch
One hallmark of Plano Overhead Garage Door’s success is their approach to customer service. Every homeowner receives a free estimate, a same-day appointment with a guaranteed 30-minute arrival window, and a personal text introducing the certified service professional en route – complete with a photo, fun facts, and a live link to track their arrival in real time. It’s thoughtful, transparent service that puts homeowners at ease.

“Winning the Consumer Choice Award for the 14th consecutive year means so much to our team because it reflects what truly matters – the trust and satisfaction of our community,” said the Plano Overhead Garage Door team. “We’re proud to keep raising the bar for what homeowners can expect from a garage door company, year after year.”

Certified Professionals, Quality You Can See
Plano Overhead Garage Door focuses exclusively on residential garage door repairs, replacements, opener upgrades, and preventative maintenance. With a showroom conveniently located off Highway 75 in Plano, customers can compare doors, touch sample panels, and see opener demonstrations before making a decision – a level of hands-on service rare in today’s online-first world.

All technicians are certified and thoroughly trained to handle everything from broken spring replacements to installing insulated doors that improve energy efficiency and enhance curb appeal. Backed by robust warranties, each job is done right the first time – with no surprise fees and no sales pressure.

Clear Pricing, No Gimmicks
Plano Overhead Garage Door has stayed true to the values it was founded on nearly 50 years ago: fair, upfront pricing and clear communication. Free estimates ensure no hidden costs, and the company’s warranties offer industry-leading protection that homeowners can trust long after the installation is complete.

This straightforward approach, combined with consistent five-star reviews, has earned the company a reputation as a trusted local partner for families across Plano, Collin County, and beyond.

Protecting Homes and Giving Back
As a family business, Plano Overhead Garage Door believes in giving back to the communities that have supported them for generations. The team participates in local events, supports neighborhood associations, and donates services when neighbors are in need – reinforcing their role not just as a service provider, but as a dependable local presence.

Building on a Legacy of Excellence
As they celebrate this 14th consecutive Consumer Choice Award, Plano Overhead Garage Door remains focused on continuous improvement. The company plans to grow its team of certified professionals, introduce new product lines featuring the latest smart-home and energy-saving technologies, and continue refining the customer experience with even more flexible scheduling and personalized service.

No matter how they grow, the company stays rooted in the same values of trust, integrity, and quality workmanship that have defined it for nearly five decades – and that have earned Plano Overhead Garage Door its remarkable track record of community recognition.

Visit the Showroom or Book a Free Estimate
Homeowners are welcome to visit the Plano showroom on Highway 75 to explore doors and openers in person, speak with knowledgeable staff, and get personalized recommendations. To learn more, request a free quote, or schedule same-day service, CLICK HERE or visit www.planooverhead.com.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

Mentavi’s innovative online asynchronous assessment, validated in a clinical study presented at the 10th World Congress on ADHD, provides clinicians with an efficient, comprehensive diagnostic mental health evaluation at an affordable price for their patients.

GRAND RAPIDS, MI / ACCESS Newswire / July 14, 2025 / Sixty percent of counties in the U.S. do not have a single psychiatrist, and 77 percent report a severe shortage, according to a 2022 study in Psychiatric Times. Primary care clinicians often have to fill this gap, but only 10-30 percent of them say they are comfortable diagnosing attention-deficit/hyperactivity disorder (ADHD) in adults. Mentavi Health offers a clinically validated diagnostic assessment for the diagnosis of ADHD in adults that closes the psychiatric care gap quickly, easily, and at an accessible price.

Mentavi Health is recognized as an innovator and national leader in online mental health diagnosis and treatment. Founded in 2018 as ADHD Online, Mentavi Health now provides a broad spectrum of services, from mental wellness checks to diagnosis and treatment.

The Mentavi Diagnostic Evaluation provides critical support to primary care clinicians, in particular those whose patients are seeking diagnosis and treatment for ADHD or other mental disorders. Patients can complete the self-paced online evaluation on their own, without a clinician present. It takes one to two hours to complete, and assesses for mental health concerns including anxiety, ADHD, and depression. The cost is less than $200.

A licensed, doctorate-level psychologist reviews the assessment responses and renders a diagnosis to the patient and designated provider in five days or less. The diagnosis can be used to develop a treatment plan, which can include medication (as warranted), coaching, and therapy with a Mentavi clinician or the patient’s own healthcare provider.

“Primary care clinicians are becoming increasingly important in adult ADHD care, but they often lack the time, tools, and resources needed to accurately diagnose the condition,” said Mentavi Health Chief Medical Officer Barry K. Herman, M.D., MMM. “Clinically validated asynchronous assessments and telehealth clinicians, as available on the Mentavi Health platform, can provide primary care clinicians with this evidence-based, accessible resource for their patients.”

Research conducted by Mentavi and presented at the 10th World Congress on ADHD in Prague, Czech Republic, validated the accuracy and reliability of the Mentavi Diagnostic Evaluation for diagnosing ADHD in adults, when compared with traditional face-to-face, in-person clinical assessments that are typically the standard of care in the field. A publication of the study results in a peer-reviewed journal is expected in the next few months.

Among the study’s findings:

• The Mentavi Diagnostic Evaluation and the clinical interview have a diagnostic agreement of 78%.

• The Mentavi Diagnostic Evaluation has a Positive Predictive Value (PPV) of 94.9%

• The Mentavi Diagnostic Evaluation identifies ADHD-positive cases more accurately than the clinical interview, with a 12% false positive rate vs. 56% for the clinical interview.

• The Mentavi Diagnostic Evaluation is more conservative than the clinical interview, meaning it does not over-diagnose ADHD in adults.

The Mentavi Diagnostic Evaluation is based on the latest research and practices. It was developed using more than a dozen validated screening instruments and specific questions aligned with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria to diagnose a broad range of mental health conditions, including ADHD. Study results demonstrate that an online asynchronous assessment, such as the Mentavi Health tool, is a reliable, accurate, and trusted tool for diagnosing ADHD in adults.

“As value-based care becomes the norm, primary care teams need scalable tools that deliver measurable impact,” said Keith Brophy, CEO of Mentavi Health. “Our diagnostic solution helps practices identify and treat mental health conditions earlier, supporting better patient outcomes and stronger performance on quality metrics.”

Mentavi Health’s core mission is to increase access to accurate, efficient, and evidence-based mental health assessments. With ADHD in adults significantly underdiagnosed and undertreated, the Mentavi Diagnostic Evaluation will aid clinicians with their role in the diagnosis and treatment of this and related disorders.

For more information, visit Mentavi Health or ADHD Online.

About Mentavi Health
Established as ADHD Online in 2018, Mentavi Health has evolved to encompass a broader range of mental health services. With the mission to make high-quality ADHD assessments accessible to all, Mentavi has grown to address not only ADHD but also the most common related mental health conditions. The nationwide Mentavi Diagnostic Evaluation and various treatment options showcase the company’s commitment to providing comprehensive, accessible, compliant online mental health care. For more information, visit mentavi.com.

SOURCE: Mentavi Health

View the original press release on ACCESS Newswire

SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that the design of the adaptive clinical trial protocol for the treatment of MPox Virus Clade Ia and Ib infections and disease is nearly complete.

The adaptive clinical trial is designed to provide information on three important aspects in a single, compact clinical trial:

1. safe and effective dosing regimen in patients,

2. safety and tolerability of the drug in patients, and

3. antiviral effectiveness of the drug in patients.

The overall clinical trial will enroll approximately 80 patients.

“This is an important milestone towards filing of the clinical trial application and starting the clinical trial,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, “Our CRO and the Principal Investigator have created a marvelous design that is both frugal and efficient while providing all of the information necessary for understanding the safety and effectiveness of NV-387 for treating MPox disease.”

Currently there is no drug approved for the treatment of MPox disease that is actually effective for treating the disease.

NV-387, if it shows effectiveness, will be the very first drug that has shown effectiveness in human clinical trial of an orthopoxvirus.

If NV-387 is found to be effective in this Phase II clinical trial, the Company intends to continue further development of NV-387 for treatment of orthopoxvirus infections under a US FDA IND towards studies as needed for regulatory approval of NV-387 for the treatment of MPox as well as Smallpox indications. The Company intends to obtain regulatory approval in the African Region as well, which is likely to arrive before a US approval, and also seek approvals in the European Union and other countries and regions.

MPox is an Orphan disease in the USA and treatment of MPox by NV-387 is eligible for Orphan Drug Designation by the US FDA with attendant benefits.

Smallpox is a bioterrorism agent of concern in the USA as well as across the world and is an important revenue opportunity for the Company. Tecovirimat sales to the US Government alone have netted SIGA, the drug holder, over $600 million through December 31, 2024, according to SIGA’s annual report to the SEC ^[1] .

The adaptive, randomized, SOC controlled clinical trial will proceed in two parts:

In Phase IIa part, an oral dose of the drug NV-387 given twice daily initially for six days will be compared with the standard of care (SOC) at the hospital for treatment of MPox disease. Patients will be sequestered in the hospital and will be evaluated daily for clinical drug safety and tolerability parameters, and clinical MPox disease evaluation parameters. Additionally, lab evaluations including clinical blood chemistry, CBC, cytokines, urinalysis, ECG, X-rays when necessary, and virological assays will be conducted every 3 days. Based on the results, the Principal Investigator will determine whether additional days of drug dosing can be well tolerated and can improve on effectiveness. If so, the patients will continue to receive same dosing for six more days with same evaluations. The patients will be followed until full resolution of the MPox disease.

There will be two arms in this Phase IIa: The New Treatment Arm of 10 patients with NV-387 dosing plus SOC and the control SOC Arm of 10 patients. The dosing regimen for Phase IIb will be determined on the basis of Phase IIa results.

In the Phase IIb part, the clinical trial will be in a 2:1 randomized patients base with approximately 40 subjects in the New Treatment Arm and 20 patients in the SOC Arm. Evaluations will be similar to those in Phase IIa, with more emphasis given to specific points that may have come up in Phase IIa regarding safety, tolerability, as well as efficacy.

The Phase IIa will be conducted at a single site in Democratic Republic of Congo (DRC). Phase IIb may be expanded to include additional sites within DRC as well as other countries experiencing severe MPox outbreak in the African Region.

The “NV-387 Oral Gummies” drug product formulation will be employed in the Phase II. This is a soft solid formulation that is designed to stick in the oral cavity and dissolve naturally over time, with no solid object (pill or capsule) swallowing necessary. This is important for MPox because MPox causes lesions on mucosal surfaces that make swallowing painful and difficult. MPox is primarily known for the explicit characteristic painful rash on the external skin, but it is a significantly more severe disease than just a skin rash.

Two drugs, Tecovirimat and Brincidofovir were approved by the US FDA for Smallpox and MPox on the basis of the US FDA “Animal Rule,” i.e. based on animal infection and treatment studies only to demonstrate efficacy, and a safety/tolerability human clinical trial.

Tecovirimat failed in clinical trials for the treatment of MPox with no improvement over the standard of care. Brincidofovir was abandoned in a clinical trial of MPox due to first three patients coming down with drug induced liver injury. Despite this, brincidofovir was recently resurrected under an international coalition led by US CDC and first patient was dosed around January 2025 in the “MOSA” clinical trial ^[2] . The topline results were expected to be announced as early as CY Q1 (March 2025) and efficacy topline data were expected no later than CY Q2 (June, 2025). No press releases post initiation of the MOSA clinical trial could be found.

The MPox virus circulating in DRC and neighboring regions is of Clade 1a and Clade 1b subtypes, with the latter predominant. Clade 1b is more transmissible of the two, which is why it has resulted in a sustained epidemic. The MPox Clade 1a case fatality rate (CFR) is about 3%-11% whereas the CFR for Clade 1b is about 1%. The MPox Clade 2b is the virus causing continuing cases in the Western world, which causes a much less severe disease than Clade 1a/1b and has a very low CFR, according to CDC. Sporadic cases of Clade 1 in the Western world continue to occur. Four separate travel-related MPox Clade 1 cases reported in the USA that did not result in any further spread, since November 2024, according to the CDC ^[3] .

Clearly, the threat of MPox Clade 1 causing a potential epidemic in the USA cannot be ignored, and readiness with a drug that works against the same is important to achieve.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

View the original press release on ACCESS Newswire